JP2024506684A5 - - Google Patents
Info
- Publication number
- JP2024506684A5 JP2024506684A5 JP2023548891A JP2023548891A JP2024506684A5 JP 2024506684 A5 JP2024506684 A5 JP 2024506684A5 JP 2023548891 A JP2023548891 A JP 2023548891A JP 2023548891 A JP2023548891 A JP 2023548891A JP 2024506684 A5 JP2024506684 A5 JP 2024506684A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149901P | 2021-02-16 | 2021-02-16 | |
| US63/149,901 | 2021-02-16 | ||
| US202163275163P | 2021-11-03 | 2021-11-03 | |
| US63/275,163 | 2021-11-03 | ||
| PCT/US2022/016403 WO2022177877A1 (en) | 2021-02-16 | 2022-02-15 | Dosage regimens for parp7 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506684A JP2024506684A (ja) | 2024-02-14 |
| JP2024506684A5 true JP2024506684A5 (https=) | 2025-02-25 |
Family
ID=80449181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548891A Pending JP2024506684A (ja) | 2021-02-16 | 2022-02-15 | Ｐａｒｐ７阻害物質の投与レジメン |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20220265654A1 (https=) |
| EP (1) | EP4294399A1 (https=) |
| JP (1) | JP2024506684A (https=) |
| KR (1) | KR20230146593A (https=) |
| TW (1) | TW202245777A (https=) |
| WO (1) | WO2022177877A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202245777A (zh) * | 2021-02-16 | 2022-12-01 | 美商律幫治療股份有限公司 | Parp7抑制劑之給藥方案 |
| EP4570806A1 (en) * | 2022-08-09 | 2025-06-18 | Kangbaida (Sichuan) Biotechnology Co., Ltd. | Composition of piperazine compound and pd-1 inhibitor or pd-l1 inhibitor and use thereof in treating tumors |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7273791B2 (ja) * | 2017-04-10 | 2023-05-15 | シエラ オンコロジー， インコーポレイテッド | 腫瘍成長を阻害するＣＨＫ１（ＳＲＡ７３７）／ＰＡＲＰｉ組み合わせ方法 |
| JP2020525427A (ja) * | 2017-06-21 | 2020-08-27 | エックス４ ファーマシューティカルズ， インコーポレイテッド | 癌を処置するための方法 |
| FI3788040T3 (fi) * | 2018-04-30 | 2023-06-13 | Ribon Therapeutics Inc | Pyridatsinoneja parp7-inhibiittoreina |
| WO2020223229A1 (en) * | 2019-04-29 | 2020-11-05 | Ribon Therapeutics, Inc. | Solid forms of a parp7 inhibitor |
| TW202245777A (zh) * | 2021-02-16 | 2022-12-01 | 美商律幫治療股份有限公司 | Parp7抑制劑之給藥方案 |
-
2022
- 2022-02-15 TW TW111105389A patent/TW202245777A/zh unknown
- 2022-02-15 US US17/671,714 patent/US20220265654A1/en not_active Abandoned
- 2022-02-15 JP JP2023548891A patent/JP2024506684A/ja active Pending
- 2022-02-15 EP EP22706210.6A patent/EP4294399A1/en active Pending
- 2022-02-15 WO PCT/US2022/016403 patent/WO2022177877A1/en not_active Ceased
- 2022-02-15 KR KR1020237031337A patent/KR20230146593A/ko active Pending
-
2023
- 2023-09-22 US US18/371,626 patent/US20240325391A1/en active Pending
-
2024
- 2024-05-03 US US18/654,312 patent/US20250064803A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506684A5 (https=) | ||
| JP2007515469A5 (https=) | ||
| JP2024074963A5 (https=) | ||
| CN108601831A (zh) | 一种抗pd-1抗体和vegfr抑制剂联合在制备治疗癌症的药物中的用途 | |
| ZA200601757B (en) | Methods of inducing terminal differentiation | |
| US12281085B2 (en) | Bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| EP4212160A1 (en) | Use of chiauranib in combination with immune checkpoint inhibitor in antitumor therapy | |
| JP2018507243A5 (https=) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| Lu et al. | Pharmacokinetic drug interactions of integrase strand transfer inhibitors | |
| JP2021509395A5 (https=) | ||
| CN101939001B (zh) | 用于治疗卵巢癌的含有紫杉醇的组合 | |
| JP2010538066A5 (https=) | ||
| JP2023102786A5 (https=) | ||
| CN101747305B (zh) | 硝克柳胺化合物晶v型、其制法和其药物组合物与用途 | |
| TW202110448A (zh) | Ｐａｒｐ抑制劑聯合ｖｅｇｆｒ抑制劑用於治療卵巢癌或乳腺癌的用途 | |
| CN111840291A (zh) | 一种在肿瘤治疗中具有增效作用的化合物的应用 | |
| JP2022177119A5 (https=) | ||
| JP2022542725A (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| WO2021023291A1 (zh) | 原黄素在肺癌治疗中的应用 | |
| CN114340672B (zh) | 包含hdac抑制剂和抗pd1抗体或抗pd-l1抗体的药物组合物 | |
| JP2025507219A (ja) | がんを処置するためのイバルチノスタット（ｉｖａｌｔｉｎｏｓｔａｔ）の使用 | |
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| CN111569078A (zh) | Sirt1抑制剂在vegfr抑制剂与免疫检查点抑制剂联用引起的副作用上的应用 | |
| JPWO2022250070A5 (https=) |